HemaB

Hemab Therapeutics

This biotechnology company develops prophylactic antibody-based therapies for patients with rare bleeding and thrombotic disorders such as Glanzmann thrombasthenia and von Willebrand disease.

Prophylix Pharma AS

The company develops antibody-based prophylactic treatments for fetal and neonatal alloimmune thrombocytopenia to prevent life-threatening bleeding and brain injury in newborns.

ProFactor Pharma

This company develops recombinant Factor VIII to treat haemophilia A in patients who currently lack access to affordable medication.

Tectonic Therapeutic

This biotechnology firm develops protein and antibody therapies targeting G-protein coupled receptors to treat patients with pulmonary hypertension and genetic bleeding disorders.

Prophylix Pharma

This company develops antibody therapies to treat fetal and neonatal alloimmune thrombocytopenia in unborn babies and newborns.

Imara

This biopharmaceutical company develops oral small-molecule therapies to treat patients with rare genetic blood disorders, including sickle cell disease and beta thalassemia.

Be Biopharma

This company develops engineered B cell medicines to treat patients with hemophilia B, genetic diseases, and cancer.

RougeTx

This biotechnology company develops small-molecule therapies that restore vascular stability to treat patients with hereditary haemorrhagic telangiectasia and other bleeding disorders.